These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 23433636

  • 1. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK, Quinn DI.
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [Abstract] [Full Text] [Related]

  • 2. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK.
    Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [Abstract] [Full Text] [Related]

  • 5. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B.
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):42-56. PubMed ID: 23523056
    [Abstract] [Full Text] [Related]

  • 6. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH, Molina AM, Motzer RJ.
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
    [Abstract] [Full Text] [Related]

  • 7. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
    Bellmunt J, Dutcher J.
    Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ.
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma.
    Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, Wood AC, Ahmed K, Chintala VN, Adelaiye-Ogala R, Elbanna M, Orillion A, Chintala S, Kao C, Linehan WM, Yousef GM, Hollenhorst PC, Pili R.
    Clin Cancer Res; 2018 Dec 01; 24(23):5977-5989. PubMed ID: 30061365
    [Abstract] [Full Text] [Related]

  • 11. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M, Enokida H.
    Cancer Sci; 2020 May 01; 111(5):1607-1618. PubMed ID: 32232883
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
    Reddy GK, Mughal TI, Rini BI.
    Clin Genitourin Cancer; 2006 Sep 01; 5(2):110-3. PubMed ID: 17026798
    [Abstract] [Full Text] [Related]

  • 14. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.
    Ann Oncol; 2014 Mar 01; 25(3):663-668. PubMed ID: 24458473
    [Abstract] [Full Text] [Related]

  • 15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 01; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 16. Optimal management of metastatic renal cell carcinoma: current status.
    Escudier B, Albiges L, Sonpavde G.
    Drugs; 2013 Apr 01; 73(5):427-38. PubMed ID: 23572408
    [Abstract] [Full Text] [Related]

  • 17. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo.
    Ye X, Ruan JW, Huang H, Huang WP, Zhang Y, Zhang F.
    Aging (Albany NY); 2020 May 18; 12(10):9489-9499. PubMed ID: 32421688
    [Abstract] [Full Text] [Related]

  • 18. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.
    Oncology; 2013 May 18; 85(1):8-13. PubMed ID: 23797151
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 18; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 20. Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.
    Coinu A, Petrelli F, Barni S.
    Expert Rev Anticancer Ther; 2016 Jul 18; 16(1):33-43. PubMed ID: 26535485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.